symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ALZN,0.208,0.012522,206671,20163540,0,0.186-1.32,0.0075,"Alzamend Neuro, Inc.",USD,0001677077,US02262M3088,02262M308,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.alzamend.com,"Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.",Mr. Stephan  Jackman,Healthcare,US,4,844 722 6333,3500 Lenox Road NE,Atlanta,GA,30326,,0,https://financialmodelingprep.com/image-stock/ALZN.png,2021-06-15,False,False,True,False,False
